(PHM) Pharma Mar S.A. - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: MC (Spain) | Market Cap: 1.734m EUR | Total Return: 16.3% in 12m
Avg Turnover: 6.51M
Qual. Beats: 0
Rev. Trend: 76.2%
Qual. Beats: 0
Warnings
Earnings expected to drop: P/E 21.7 → Forward 54.1
Tailwinds
Confidence
Pharma Mar, S.A. is a Madrid-based biopharmaceutical company specializing in the discovery and commercialization of marine-derived compounds for oncology and RNA interference. Its portfolio includes Yondelis for soft tissue sarcoma, Zepzelca for small cell lung cancer, and Aplidin for multiple myeloma. The company maintains a global presence across Europe and the United States, supported by a pipeline of Phase I to Phase III clinical trials targeting solid tumors and macular degeneration.
The biotechnology sector relies heavily on high research and development (R&D) expenditures and the successful navigation of multi-phase clinical trials to secure regulatory approval. Pharma Mar’s business model is distinct for its focus on marine biotechnology, which involves sourcing bioactive molecules from sea organisms to address unmet medical needs in oncology.
For a more detailed breakdown of the companys fundamentals and valuation, you may wish to consult ValueRay.
- Zepzelca commercial expansion and royalty growth drive oncology revenue performance
- LAGOON Phase III clinical trial results determine long-term small cell lung cancer valuation
- Generic competition for Yondelis impacts core product margins and market share
- FDA and EMA regulatory approvals dictate entry into major global pharmaceutical markets
- R&D expenditure for Phase I and II pipelines influences short-term cash flow volatility
| Net Income: 80.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.15 > 0.02 and ΔFCF/TA 20.48 > 1.0 |
| NWC/Revenue: 81.72% < 20% (prev 89.06%; Δ -7.34% < -1%) |
| CFO/TA 0.18 > 3% & CFO 68.0m > Net Income 80.5m |
| Net Debt (-117.5m) to EBITDA (69.2m): -1.70 < 3 |
| Current Ratio: 3.06 > 1.5 & < 3 |
| Outstanding Shares: last quarter (17.2m) vs 12m ago -0.54% < -2% |
| Gross Margin: 92.66% > 18% (prev 0.94%; Δ 9.17k% > 0.5%) |
| Asset Turnover: 62.73% > 50% (prev 52.70%; Δ 10.03% > 0%) |
| Interest Coverage Ratio: 28.96 > 6 (EBITDA TTM 69.2m / Interest Expense TTM 2.11m) |
| A: 0.48 (Total Current Assets 273.5m - Total Current Liabilities 89.2m) / Total Assets 385.3m |
| B: 0.61 (Retained Earnings 235.4m / Total Assets 385.3m) |
| C: 0.17 (EBIT TTM 61.1m / Avg Total Assets 359.4m) |
| D: 1.82 (Book Value of Equity 246.3m / Total Liabilities 135.6m) |
| Altman-Z'' = 8.18 = AAA |
| DSRI: 0.85 (Receivables 40.0m/36.8m, Revenue 225.4m/175.7m) |
| GMI: 1.02 (GM 92.66% / 94.41%) |
| AQI: 1.15 (AQ_t 0.14 / AQ_t-1 0.12) |
| SGI: 1.28 (Revenue 225.4m / 175.7m) |
| TATA: 0.03 (NI 80.5m - CFO 68.0m) / TA 385.3m) |
| Beneish M = -2.81 (Cap -4..+1) = A |
As of May 24, 2026, the stock is trading at EUR 100.00 with a total of 63,930 shares traded.
Over the past week, the price has changed by +4.67%,
over one month by +7.18%,
over three months by +28.08% and
over the past year by +16.34%.
Pharma Mar S.A. has no consensus analysts rating.
P/E Trailing = 21.6883
P/E Forward = 54.0541
P/S = 7.6921
P/B = 6.8552
P/EG = 0.3119
Revenue TTM = 225.4m EUR
EBIT TTM = 61.1m EUR
EBITDA TTM = 69.2m EUR
Long Term Debt = 33.2m EUR (from longTermDebt, last quarter)
Short Term Debt = 13.1m EUR (from shortTermDebt, last quarter)
Debt = 50.4m EUR (from shortLongTermDebtTotal, last quarter) + Leases 2.85m
Net Debt = -117.5m EUR (calculated: Debt 50.4m - CCE 167.9m)
Enterprise Value = 1.62b EUR (1.73b + Debt 50.4m - CCE 167.9m)
Interest Coverage Ratio = 28.96 (Ebit TTM 61.1m / Interest Expense TTM 2.11m)
EV/FCF = 27.98x (Enterprise Value 1.62b / FCF TTM 57.8m)
FCF Yield = 3.57% (FCF TTM 57.8m / Enterprise Value 1.62b)
FCF Margin = 25.63% (FCF TTM 57.8m / Revenue TTM 225.4m)
Net Margin = 35.70% (Net Income TTM 80.5m / Revenue TTM 225.4m)
Gross Margin = 92.66% ((Revenue TTM 225.4m - Cost of Revenue TTM 16.6m) / Revenue TTM)
Gross Margin QoQ = 91.47% (prev 93.59%)
Tobins Q-Ratio = 4.20 (Enterprise Value 1.62b / Total Assets 385.3m)
Interest Expense / Debt = 4.19% (Interest Expense 2.11m / Debt 50.4m)
Taxrate = 4.07% (65.0k / 1.60m)
NOPAT = 58.6m (EBIT 61.1m * (1 - 4.07%))
Current Ratio = 3.06 (Total Current Assets 273.5m / Total Current Liabilities 89.2m)
Debt / Equity = 0.20 (Debt 50.4m / totalStockholderEquity, last quarter 249.7m)
Debt / EBITDA = -1.70 (Net Debt -117.5m / EBITDA 69.2m)
Debt / FCF = -2.03 (Net Debt -117.5m / FCF TTM 57.8m)
Total Stockholder Equity = 225.1m (last 4 quarters mean from totalStockholderEquity)
RoA = 22.39% (Net Income 80.5m / Total Assets 385.3m)
RoE = 35.74% (Net Income TTM 80.5m / Total Stockholder Equity 225.1m)
RoCE = 23.66% (EBIT 61.1m / Capital Employed (Equity 225.1m + L.T.Debt 33.2m))
RoIC = 41.50% (NOPAT 58.6m / Invested Capital 141.2m)
WACC = 7.59% (E(1.73b)/V(1.78b) * Re(7.69%) + D(50.4m)/V(1.78b) * Rd(4.19%) * (1-Tc(0.04)))
Discount Rate = 7.69% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -62.87 | Cagr: -1.09%
[DCF] Terminal Value 75.44% ; FCFF base≈57.8m ; Y1≈58.0m ; Y5≈61.5m
[DCF] Fair Price = 62.02 (EV 955.8m - Net Debt -117.5m = Equity 1.07b / Shares 17.3m; r=8.35% [WACC [floored]]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.07 | # QB: 0
Revenue Correlation: 76.21 | Revenue CAGR: 10.32% | SUE: -0.03 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.29 | Chg30d=+54.37% | Revisions=-20% | Analysts=3
EPS next Quarter (2026-09-30): EPS=0.40 | Chg30d=+166.67% | Revisions=-20% | Analysts=3
EPS current Year (2026-12-31): EPS=3.25 | Chg30d=+28.99% | Revisions=+14% | GrowthEPS=-24.3% | GrowthRev=+7.5%
EPS next Year (2027-12-31): EPS=7.38 | Chg30d=+3.03% | Revisions=+14% | GrowthEPS=+126.9% | GrowthRev=+36.2%
[Analyst] Revisions Ratio: -20%